Samsung BioLogics - Public Comps and Valuation Multiples

Samsung BioLogics Overview

About Samsung BioLogics

Samsung BioLogics Co Ltd is a biopharmaceutical company engaged in drug development and manufacturing services. The company operates two segments: Biopharmaceutical Development and Commercialization, and Contract Development and Manufacturing Organization (CDMO). The Biopharmaceutical Development and Commercialization segment focuses on developing and commercializing biosimilars across therapeutic areas, including autoimmune, oncology, ophthalmology, and hematology. The Contract Development and Manufacturing Organization (CDMO) segment provides biopharmaceutical contract manufacturing along with cell line and process development services. It generates the majority of its revenue from the CDMO segment.

Founded

2011

HQ

Employees

5.0K+

Website

samsungbiologics.com

Sectors

Contract Research & Manufacturing
BioTech

Financials

LTM Revenue $4.0B

LTM EBITDA $1.9B

EV

$61.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Samsung BioLogics Financials

As of December 2025, Samsung BioLogics reported last 12-month revenue of $4.0B and EBITDA of $1.9B.

In the same period, Samsung BioLogics generated $2.4B in LTM gross profit and $1.2B in net income.

See Samsung BioLogics valuation multiples based on analyst estimates

Samsung BioLogics P&L

In the most recent fiscal year, Samsung BioLogics reported revenue of $3.1B and EBITDA of $1.4B.

Samsung BioLogics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Samsung BioLogics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$4.0B	XXX	$3.1B	XXX	XXX	XXX
Gross Profit	$2.4B	XXX	$1.6B	XXX	XXX	XXX
Gross Margin	60%	XXX	50%	XXX	XXX	XXX
EBITDA	$1.9B	XXX	$1.4B	XXX	XXX	XXX
EBITDA Margin	46%	XXX	44%	XXX	XXX	XXX
EBIT	$1.5B	XXX	$911M	XXX	XXX	XXX
EBIT Margin	38%	XXX	29%	XXX	XXX	XXX
Net Profit	$1.2B	XXX	$748M	XXX	XXX	XXX
Net Margin	29%	XXX	24%	XXX	XXX	XXX
Net Debt	XXX	XXX	$655M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Samsung BioLogics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $4.0B. EBITDA for the last twelve months was $1.9B. In the most recent fiscal year, Samsung BioLogics achieved $3.1B in revenue and $1.4B in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$4.0B	Analyst estimates available to subscribers	$3.1B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$2.4B	Analyst estimates available to subscribers	$1.6B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	60.3% gross margin	Analyst estimates available to subscribers	50.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$1.9B	Analyst estimates available to subscribers	$1.4B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	46.4% EBITDA margin	Analyst estimates available to subscribers	44.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$1.5B	Analyst estimates available to subscribers	$911M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	37.6% EBIT margin	Analyst estimates available to subscribers	29.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$1.2B	Analyst estimates available to subscribers	$748M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	28.8% net profit margin	Analyst estimates available to subscribers	23.8% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$655M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Samsung BioLogics

This financial data table provides comprehensive performance metrics for Samsung BioLogics, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Samsung BioLogics generated $4.0B in revenue over the last twelve months.
The company achieved $1.9B in EBITDA over the last twelve months.
Gross profit for the last twelve months was $2.4B.
Net income over the last twelve months reached $1.2B.

Fiscal Year Performance

In the most recent fiscal year, Samsung BioLogics reported $3.1B in total revenue.
Fiscal year EBITDA was $1.4B.
The company maintained a gross profit margin of 50.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 44.4%.
Net profit margin reached 23.8% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Samsung BioLogics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Samsung BioLogics Stock Performance

Samsung BioLogics has current market cap of KRW 90.13T (or $62.2B), and EV of KRW 89.39T (or $61.7B).

Market Cap Evolution

Samsung BioLogics Stock Data

As of January 16, 2026, Samsung BioLogics's stock price is KRW 1947000 (or $1344).

See Samsung BioLogics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$61.7B	$62.2B	XXX	XXX	XXX	XXX	$22.93

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Samsung BioLogics Valuation Multiples

Samsung BioLogics's trades at 15.4x EV/Revenue multiple, and 33.2x EV/EBITDA.

See valuation multiples for Samsung BioLogics and 15K+ public comps

Samsung BioLogics Financial Valuation Multiples

As of January 16, 2026, Samsung BioLogics has market cap of $62.2B and EV of $61.7B.

Equity research analysts estimate Samsung BioLogics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Samsung BioLogics has a P/E ratio of 54.1x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$62.2B	XXX	$62.2B	XXX	XXX	XXX
EV (current)	$61.7B	XXX	$61.7B	XXX	XXX	XXX
EV/Revenue	15.4x	XXX	15.4x	XXX	XXX	XXX
EV/EBITDA	33.2x	XXX	33.2x	XXX	XXX	XXX
EV/EBIT	41.1x	XXX	41.1x	XXX	XXX	XXX
EV/Gross Profit	25.6x	XXX	n/a	XXX	XXX	XXX
P/E	54.1x	XXX	54.1x	XXX	XXX	XXX
EV/FCF	94.5x	XXX	94.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Samsung BioLogics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Samsung BioLogics Margins & Growth Rates

Samsung BioLogics's last 12 month revenue growth is -8%

Samsung BioLogics's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.1M for the same period.

Samsung BioLogics's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Samsung BioLogics's rule of X is 26% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Samsung BioLogics and other 15K+ public comps

Samsung BioLogics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	-8%	XXX	2%	XXX	XXX	XXX
EBITDA Margin	46%	XXX	46%	XXX	XXX	XXX
EBITDA Growth	11%	XXX	26%	XXX	XXX	XXX
Rule of 40	38%	XXX	38%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	26%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.6M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	6%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	21%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial